F. Struyf

发表

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Henry C Kitchener, Bart Spiessens, Frank Struyf, 2007, The Lancet.

Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

C. Wheeler, S. Garland, X. Castellsagué, 2013, PloS one.

Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals.

M. Van Ranst, L. Corey, P. Spear, 2002, The Journal of infectious diseases.

Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.

P. van Damme, A. García-Sastre, P. Palese, 2022, The Lancet. Infectious diseases.

Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland

M. Lehtinen, D. Apter, E. Pukkala, 2021, Cancer medicine.

Usefulness of Immunochromatographic Detection of Antibodies to Mycobacterium tuberculosis as an Adjunct to Auramine Staining for Rapid Diagnosis of Tuberculosis in a Low-Prevalence Setting

M. Van Ranst, F. Struyf, J. Verhaegen, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial

M. Lehtinen, D. Apter, F. Struyf, 2019, International journal of cancer.

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial

F. Zhu, F. Struyf, Xun Zhang, 2020, Human vaccines & immunotherapeutics.

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials

M. Lehtinen, J. Dillner, D. Apter, 2017, BMJ Open.

Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.

M. Lehtinen, G. Garnett, D. Apter, 2015, Vaccine.

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

P. Hillemanns, M. Dionne, F. Struyf, 2014, Human vaccines & immunotherapeutics.

Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.

F. Struyf, Naveen Karkada, D. Borys, 2019, The Pediatric infectious disease journal.

Strategies for continuous evaluation of the benefit–risk profile of HPV-16/18-AS04-adjuvanted vaccine

F. Struyf, G. Dubin, D. Rosillon, 2014, Expert review of vaccines.

One virus, one lesion—individual components of CIN lesions contain a specific HPV type

W. Quint, C. van Hoof, F. Struyf, 2012, The Journal of pathology.

Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.

H. Kitchener, M. Lehtinen, D. Harper, 2012, Gynecologic oncology.

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.

S. Wacholder, A. Hildesheim, R. Herrero, 2014, Vaccine.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

D. Lowy, C. Wheeler, S. Wacholder, 2015, The Lancet. Oncology.

Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study

F. Struyf, N. Folschweiller, Naveen Karkada, 2020, Asia-Pacific journal of clinical oncology.

Fewer than three doses of HPV vaccine - Authors' reply.

C. Wheeler, A. Hildesheim, A. Kreimer, 2015, The Lancet. Oncology.

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

M. Einstein, R. Sperling, F. Struyf, 2014, Human vaccines & immunotherapeutics.

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

H. Schuitemaker, D. Heerwegh, J. Sadoff, 2021, The New England journal of medicine.

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

H. Schuitemaker, R. Baric, M. Lifton, 2021, Nature.

Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine

H. Schuitemaker, F. Struyf, M. Ryser, 2022, Immunological reviews.

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

H. Fennema, H. Schuitemaker, J. Stoddard, 2021, The New England journal of medicine.

Prevalence of CCR5 and CCR2 HIV-Coreceptor Gene Polymorphisms in Belgium

M. Van Ranst, J. Wuu, F. Struyf, 2000, Human Heredity.

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

H. Schuitemaker, P. van Damme, M. McElrath, 2021, The New England journal of medicine.

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

M. Lehtinen, D. Harper, S. Garland, 2013, The Journal of infectious diseases.

Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn’s disease

P. Lemey, P. Rutgeerts, S. Vermeire, 2001, Genes and Immunity.

Mannan-binding lectin gene polymorphisms in ulcerative colitis and Crohn's disease

P. Lemey, P. Rutgeerts, S. Vermeire, 2001 .

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Mathieu Le Gars, H. Schuitemaker, P. van Damme, 2020, medRxiv.

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Lindsay N. Carpp, M. Andrasik, J. Kublin, 2022, Nature Microbiology.

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

H. Schuitemaker, D. Heerwegh, J. Sadoff, 2022, Vaccine.

Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting

Mathieu Le Gars, H. Schuitemaker, D. Heerwegh, 2021, medRxiv.

Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials.

C. Wheeler, M. Lehtinen, W. Quint, 2020, The Journal of infectious diseases.

E4 Antibodies Facilitate Detection and Type-Assignment of Active HPV Infection in Cervical Disease

W. Quint, C. van Hoof, F. Struyf, 2012, PloS one.

Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial

C. Wheeler, H. Kitchener, M. Lehtinen, 2007 .

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine: Pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials.

C. Wheeler, W. Quint, J. Sampson, 2019, Journal of the National Cancer Institute.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

B Romanowski, H. Kitchener, M. Lehtinen, 2009, The Lancet.

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years

Junzhi Wang, Hui Zhao, Juan Li, 2014, Human vaccines & immunotherapeutics.

Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine

F. Struyf, D. Rosillon, A. Guignard, 2020, Pharmacoepidemiology and drug safety.

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

C. Chiu, Li-Min Huang, F. Struyf, 2019, Human vaccines & immunotherapeutics.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.

R. Rouzier, N. Tan, F. Struyf, 2018, Vaccine.

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

C. Wheeler, M. Lehtinen, D. Harper, 2017, Journal of the National Cancer Institute.

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

P. Hillemanns, C. Giaquinto, T. Puthanakit, 2017, The Journal of infectious diseases.

Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial

Hong Wang, F. Chen, F. Zhu, 2016, Cancer medicine.

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

D. Harper, D. Apter, J. Paavonen, 2016, Expert review of vaccines.

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years

C. Giaquinto, T. Puthanakit, C. Chiu, 2016, The Journal of infectious diseases.

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

P. Hillemanns, M. Dionne, F. Struyf, 2015, Human vaccines & immunotherapeutics.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial

R. Rouzier, N. Tan, F. Struyf, 2015, Human vaccines & immunotherapeutics.

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

C. Wheeler, H. Kitchener, M. Lehtinen, 2015, Clinical and Vaccine Immunology.

Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

Frank Struyf, Brigitte Colau, Cosette M Wheeler, 2014, Clinical and Vaccine Immunology.

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women

W. Quint, H. Yoshikawa, F. Struyf, 2014, Human vaccines & immunotherapeutics.

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

F. Struyf, G. Dubin, L. Baril, 2014, Pharmacoepidemiology and drug safety.

Efficacy of the human papillomavirus ( HPV )-16 / 18 AS 04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women Open follow-up of a randomized clinical trial up to 4 years post-vaccination

W. Quint, H. Yoshikawa, F. Struyf, 2014 .

Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease

P. Rutgeerts, S. Vermeire, M. Van Ranst, 2001, Human Genetics.

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine

H. Schuitemaker, P. Goepfert, D. Heerwegh, 2022, The Journal of infectious diseases.

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

E. Kerwin, J. Tica, F. Struyf, 2022, The Journal of infectious diseases.

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

H. Schuitemaker, M. Robb, P. Goepfert, 2022, The New England journal of medicine.

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, International journal of cancer.

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Ahmed Abdul Azim, D. Lauffenburger, H. Schuitemaker, 2021, JAMA.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

C. Wheeler, H. Kitchener, W. Quint, 2016, The Lancet. Infectious diseases.

Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials

S. Wacholder, M. Sherman, M. Schiffman, 2018, The Journal of infectious diseases.

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study

M. Einstein, M. Levin, F. Struyf, 2014, Human vaccines & immunotherapeutics.

Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study

C. Wheeler, D. Harper, C. Vallejos, 2016, International journal of cancer.

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age

A. Kaufmann, F. Struyf, T. Schwarz, 2017, Cancer medicine.

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant.

J. Sadoff, F. Struyf, M. Douoguih, 2021, The New England journal of medicine.

Glycoprotein D-Independent Spread of Pseudorabies Virus Infection in Cultured Peripheral Nervous System Neurons in a Compartmented System

L. Enquist, P. Spear, T. H. Ch’ng, 2007, Journal of Virology.

Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial

Lindsay N. Carpp, Mathieu Le Gars, M. Andrasik, 2022, medRxiv.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

M. Lehtinen, S. Garland, X. Castellsagué, 2016, International journal of cancer.

Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4–6-year-old Girls: Results to Month 12 From a Randomized Trial

F. Struyf, L. Romano-Mazzotti, S. Damaso, 2018, The Pediatric infectious disease journal.

Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials.

C. Wheeler, M. Lehtinen, W. Quint, 2020, The Journal of infectious diseases.

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19

Mathieu Le Gars, H. Schuitemaker, D. Heerwegh, 2021, medRxiv.

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years

M. Lehtinen, D. Apter, F. Struyf, 2019, Human vaccines & immunotherapeutics.

Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial

Juan Li, F. Zhu, F. Struyf, 2014, International journal of cancer.

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial

M. Lehtinen, D. Apter, E. Pukkala, 2016, Human vaccines & immunotherapeutics.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Jack T Stapleton, Arunachalam Ilancheran, Frank Struyf, 2014, The Lancet.

Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

C. Wheeler, H. Kitchener, M. Lehtinen, 2014, The Journal of infectious diseases.

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine

F. Struyf, D. Rosillon, J. Chen, 2019, Open forum infectious diseases.

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial

C. Wheeler, M. Lehtinen, S. Garland, 2014, BMC Infectious Diseases.

Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial

F. Zhu, F. Struyf, Xun Zhang, 2019, Cancer medicine.

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study

K. Ruxrungtham, F. Struyf, G. Dubin, 2020, EClinicalMedicine.

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

Juan Li, F. Zhu, F. Struyf, 2014, International journal of cancer.

Risk of first cervical HPV infection and precancerous lesions after onset of sexual activity Castellsague

C. Wheeler, F. X. Bosch, M. Lehtinen, 2022 .

Mutations in the N-Terminal Domains of Nectin-1 and Nectin-2 Reveal Differences in Requirements for Entry of Various Alphaherpesviruses and for Nectin-Nectin Interactions

P. Spear, F. Struyf, W. Martinez, 2002, Journal of Virology.

O608 IMMUNE RESPONSE TO THE HPV‐16/18 AS04‐ADJUVANTED VACCINE ADMINISTERED AS A 2‐DOSE OR 3‐DOSE SCHEDULE UP TO 3 YEARS AFTER VACCINATION

P. Hillemanns, M. Dionne, F. Struyf, 2012 .

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naïve population

C. Wheeler, H. Kitchener, M. Lehtinen, 2009 .

Deletion of the Second Immunoglobulin-Like Domain of Nectin-1 Alters Its Intracellular Processing and Localization and Ability To Mediate Entry of Herpes Simplex Virus

P. Spear, F. Struyf, Aileen E Plate, 2005, Journal of Virology.

H. Kitchener, M. Lehtinen, X. Castellsagué, 2012, The Lancet. Oncology.

H. Kitchener, M. Lehtinen, S. Garland, 2015, Clinical and Vaccine Immunology.

One virus, one lesion—individual components of CIN lesions contain a specific HPV type

W. Quint, C. van Hoof, F. Struyf, 2012, Journal of Pathology.

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

P. Hillemanns, P. Durando, M. Dionne, 2019, The Journal of infectious diseases.

Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

M. Lehtinen, A. Hildesheim, M. Schiffman, 2021 .

Evaluation of Glucocard Memory 2 and Accutrend® Sensor Blood Glucose Meters

F. Struyf, S. Arens, Z. Zaman, 1998, Clinical chemistry and laboratory medicine.

Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies

C. Vallejos, S. Garland, X. Castellsagué, 2019, Cancer medicine.